Journal
METALLOMICS
Volume 6, Issue 5, Pages 978-995Publisher
OXFORD UNIV PRESS
DOI: 10.1039/c3mt00225j
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [21172274, 21231007, 21121061, J1103305]
- State High-Tech Development Program [2012AA020305]
- Ministry of Education of China [20100171110013, 313058]
- National Basic Research Program of China [2014CB845604]
- Fundamental Research Funds for the Central Universities
Ask authors/readers for more resources
Since the discovery of cisplatin more than 40 years ago, enormous research efforts have been dedicated to developing metal-based anticancer agents and to elucidating the mechanisms involved in the action of these compounds. Abnormal metabolism and the evasion of apoptosis are important hallmarks of malignant transformation, and the induction of apoptotic cell death has been considered to be a main pathway by which cytotoxic metal complexes combat cancer. However, many cancers have cellular defects involving the apoptotic machinery, which results in an acquired resistance to apoptotic cell death and therefore reduced chemotherapeutic effectiveness. Over the past decade, it has been revealed that a growing number of cell death pathways induced by metal complexes are not dependent on apoptosis. Metal complexes specifically triggering these alternative cell death pathways have been identified and explored as novel cancer treatment options. In this review, we discuss recent examples of metallomics studies on the different types of cell death induced by metal-based anticancer drugs, especially on the three major forms of programmed cell death ( PCD) in mammalian cells: apoptosis, autophagy and regulated necrosis, also called necroptosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available